10·YR · 2016 → 2026A decade backing breakthrough therapeutics. Read the anniversary letter.
Open letter →
Taiho VenturesEST. 2016 · MENLO PARKSubmit a deal
Corporate Venture · Taiho PharmaceuticalFUND III · $400MMENLO PARK · TOKYO2026·05·08

Where breakthrough science
meets a global pharma cap-table.

Mandate · Therapeutics · Pre-clinical → POC

We invest in early-stage oncology, immunology and urology alongside the most credible institutional life-science investors — bringing the validation, infrastructure and Asian-market reach of Taiho Pharmaceutical to the syndicate.

Submit a deal See the portfolio
FLAME · MARKPRIMARY MOTIF
FIG. 01LAB · TRANSLATIONAL
FIG. 02PORTFOLIO · BOARD ROOM
Capital · Fund III
$400M
Patient capital, balance-sheet backed by Taiho Pharmaceutical.
Vintage
10·yr
Continuous deployment since 2016 — through three market cycles.
Portfolio
38
Companies financed · 7 IPOs · 4 strategic acquisitions.
Syndicates
52
Lead investors we've stood alongside — ARCH, GV, MPM, Versant, RA.
§ 01 · Mandate

Early-stage therapeutics where science is the asset and the syndicate is the strategy.

01 — Focus

Oncology, immunology, urology.

We index hard on indications where Taiho Pharmaceutical's seventy-year scientific lineage compounds: solid tumors, novel I/O, and uro-oncology where commercial channels matter.

OncologyImmunologyUrology
02 — Stage

Preclinical through proof of concept.

$5M–$25M into Series A and B as a strategic participant. Earlier when the science calls for it; later through follow-on or build-to-buy structures.

PreclinicalPhase 1POCBuild-to-buy
03 — Structure

Syndicate, create, or acquire.

Led, co-led and followed across 50+ syndicates. Founded three operating companies. Re-acquired one of our own — Cullinan Pearl. Patient capital makes flexible structures possible.

SyndicateCo-foundLicenseM&A

Selected portfolio.

38 active & realized · 11 outcomesView the full portfolio →
Build-to-buy · Reacquired 2023
Cullinan Pearl
Solid tumor · EGFR exon 20 · Asia rights
FIG. 02 · CULLINAN PEARL · BUILD-TO-BUY · 2023
Originally co-created with Cullinan Oncology, Pearl was carved out and acquired by Taiho Pharmaceutical in 2023 — the canonical proof of our build-to-buy model.
SyndicateCullinan Oncology · Taiho Ventures · MPM
IPO · NYSE: RCUS
Arcus Biosciences
Adenosine · TIGIT · I/O combo
Strategic investor since Series C; led the Asian rights collaboration that became the foundation of Arcus's Pacific commercialization strategy.
Co-investorsForesite · Column Group · GV · Celgene
M&A · Merck
Orna Therapeutics
Circular RNA platform
Co-investorsMPM · F-Prime · Novartis
M&A · Merck KGaA
Harpoon Therapeutics
TriTAC engagers
Co-investorsMPM · ARCH · NEA
Vincerx Pharma
Bioconjugation · ADC
Public
Co-investorsBayer · Atlas · Polaris
Anaveon
IL-2 selective agonist
Series B
Co-investorsSR One · Novartis VC · HBM
Logos & case content shown for layout demonstration. Final list and outcomes provided by Taiho Ventures.Filter the full portfolio →
§ 02 · Team

Investors who built drugs before they wrote checks.

B.01PORTRAIT · 4:5
Yuki Tanaka, PhD
Managing Director
Stanford PhDEx-Genentech
Translational immunology; led three CD3 bispecific INDs.
B.02PORTRAIT · 4:5
Marcus Chen, MD
Partner, Clinical
Yale MDMSK fellow
Oncologist; PI on five Phase 1/2 solid-tumor trials.
B.03PORTRAIT · 4:5
Aoife Brennan
Partner, Operations
Wharton MBAEx-CEO
Built and exited a public biotech; advises through clinic and BD.
B.04PORTRAIT · 4:5
Hiroshi Mori, PhD
Principal, Tokyo
Univ. TokyoAsia bridge
Asian-market entry and licensing; manages co-development pipeline.

From the newsroom.

Press feed launches Q3 2026
Placeholder · 2026.07.xxA coming announcement on platform-stage immunology investment.Taiho Ventures Press · Menlo Park
Placeholder · 2026.06.xxPacific commercialization expansion — joint statement, Tokyo.Taiho Pharmaceutical & Taiho Ventures
Placeholder · 2026.05.xxTenth-anniversary letter from the Managing Director.Taiho Ventures · Editorial
§ 03 · Reach the team

Tell us where you are in the science.

01Stage
Where is the asset today?
DiscoveryPreclinicalPhase 1Phase 2 / POCPlatform-stage
02Area
Therapeutic focus
OncologyImmunologyUrologyAdjacent
03Modality
Technology / modality
Small moleculeBiologicADCCell & geneRNAPlatform
04Ask
What kind of partner are you looking for?
Syndicate participantLeadCo-creationStrategic / BD
Continue to deck uploadReplies in 5 business days · NDA on request
→